AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea
Phase 4
Completed
- Conditions
- Type 2 Diabetes MellitusInadequate Glycaemic Control
- Interventions
- First Posted Date
- 2015-06-15
- Last Posted Date
- 2019-03-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 939
- Registration Number
- NCT02471404
- Locations
- 🇸🇰
Research Site, Vrutky, Slovakia
AZD0585 Phase III Long-term Study in Japan
- First Posted Date
- 2015-06-04
- Last Posted Date
- 2018-10-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 383
- Registration Number
- NCT02463071
- Locations
- 🇯🇵
Research Site, Urasoe-shi, Japan
Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes
Phase 3
Completed
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Other: Placebo for dapagliflozin
- First Posted Date
- 2015-06-03
- Last Posted Date
- 2019-03-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 815
- Registration Number
- NCT02460978
- Locations
- 🇬🇧
Research Site, Wakefield, United Kingdom
Congenital Malformations and Maternal Use of Anti-hypertensive Medication in the United Kingdom
Completed
- Conditions
- Hypertension
- First Posted Date
- 2015-06-02
- Last Posted Date
- 2016-06-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 22000
- Registration Number
- NCT02459990
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours
Phase 3
Completed
- Conditions
- Locally Advanced or Metastatic EGFR T790M+ NSCLC
- Interventions
- First Posted Date
- 2015-05-27
- Last Posted Date
- 2023-07-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 29
- Registration Number
- NCT02454933
- Locations
- 🇨🇳
Research Site, Taipei, Taiwan
Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)
Phase 3
Active, not recruiting
- Conditions
- Non-Small-Cell Lung Carcinoma NSCLC
- Interventions
- Biological: MEDI4736 (Durvalumab)Biological: MEDI4736 (Durvalumab)+Tremelimumab
- First Posted Date
- 2015-05-25
- Last Posted Date
- 2025-06-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1118
- Registration Number
- NCT02453282
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
AZD9291 US Expanded Access Program
- Conditions
- EGFR T790M Mutation Positive NSCLC
- First Posted Date
- 2015-05-22
- Last Posted Date
- 2016-07-14
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT02451852
- Locations
- 🇺🇸
Research Site, Seattle, Washington, United States
Study to Evaluate Efficacy & Safety of Tralokinumab in Subjects With Asthma Inadequately Controlled on Corticosteroids
Phase 2
Completed
- Conditions
- Asthma
- Interventions
- Other: PlaceboBiological: Tralokinumab
- First Posted Date
- 2015-05-20
- Last Posted Date
- 2019-01-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 79
- Registration Number
- NCT02449473
- Locations
- 🇬🇧
Research Site, Southampton, United Kingdom
Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus
Phase 3
Completed
- Conditions
- Active Systemic Lupus Erythematosus
- Interventions
- Drug: PlaceboBiological: Anifrolumab
- First Posted Date
- 2015-05-18
- Last Posted Date
- 2023-01-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 373
- Registration Number
- NCT02446899
- Locations
- 🇪🇸
Research Site, Vigo, Spain
Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus
Phase 3
Completed
- Conditions
- Active Systemic Lupus Erythematosus
- Interventions
- Drug: PlaceboBiological: Anifrolumab
- First Posted Date
- 2015-05-18
- Last Posted Date
- 2023-01-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 460
- Registration Number
- NCT02446912
- Locations
- 🇬🇧
Research Site, Staffordshire, United Kingdom